The global biotechnology and pharmaceutical services outsourcing market size was estimated at USD 46.15 billion in 2023 and is projected to grow at a CAGR of 5.67% from 2024 to 2030. Rising drug development costs, diminishing internal capabilities, increasing regulatory frameworks, and low-cost service deployment to contract research organizations (CROs), and contract manufacturing organizations (CMOs) are some of the major factors driving market growth.
Post-pandemic, demand for innovative and effective therapies is increasing and driving growth. The rising drug development costs coupled with higher failure rates and growing regulatory pressure also have a significant impact on market dynamics, accelerating market growth rate. Furthermore, well-established CROs, regulatory outsourcing firms, management consulting firms, and contract manufacturers are catering to the complex demands of pharmaceutical and biotechnological sectors. Contract research and manufacturing companies are investing in personnel, infrastructure, and technology to acquire a significant share of the healthcare outsourcing market.
Increasing demand due to the ongoing patent cliff of biotechnology drugs is anticipated to fuel demand. An increasing number of end-to-end service providers, to meet the rising demand for low-cost drug development and manufacturing, is further anticipated to propel market growth. Moreover, novel drug delivery mechanisms and new product launches are anticipated to drive outsourcing demand. Many companies are opting for outsourcing owing to increasing competition in the healthcare industry. For instance, in February 2023, Lonza completed expansion of its conjugation facility in Visp, Switzerland.
The expansion included the addition of manufacturing suites & supporting infrastructure, increasing development & manufacturing capacity for bioconjugates & antibody-drug conjugates for preclinical, clinical, & commercial supply. An increasing number of R&D activities for new drug development, combination products, and other advanced medicines have increased demand for contract biotechnology and pharmaceutical services. Currently, the global pharmaceutical industry has the second-highest R&D intensity measures of any sector, which indicates that spending on R&D is increasing, and overall spending is likely to grow during the forecast period. For instance, in 2023, the 10 major pharmaceutical companies invested over USD 126.9 billion in research and development (R&D), constituting 41% of the overall research expenditure in the global biopharmaceutical sector for the previous year.
The biotechnology and pharmaceutical services outsourcing industry is characterized by a high degree of innovation. The pharmaceutical and biotechnology industry is driven by continuous advancements in technology. Novel manufacturing processes, analytical techniques, and research methodologies are developed to improve efficiency, reduce costs, and enhance the quality of biopharmaceutical products.
The market is also characterized by a high level of merger and acquisition (M&A) activity by leading players. Companies merge or acquire others in biotechnology and pharmaceutical services outsourcing sector to expand their service offerings, geographic reach, or client base. For instance, in March 2024, Lonza announced the acquisition of a large scale biologics manufacturing site from Genentech, part of Roche in the U.S. for USD 1.2 million. Through this acquisition, Lonza will broaden its manufacturing capacity of biologics to cater to increasing customer demand and gain a competitive edge in the market.
The market is characterized by a high impact of regulations. The pharmaceutical and biotechnology sectors are subject to strict quality and safety standards to ensure efficacy and safety of drugs and biologics. Regulatory agencies establish and enforce these standards, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
The market is characterized by a high impact on service expansion. Biotechnology and pharmaceutical companies prefer outsourcing partners that offer integrated solutions, covering a wide spectrum of services. Service expansion allows outsourcing providers to offer end-to-end solutions, encompassing discovery, clinical trials, preclinical development, regulatory affairs, manufacturing, and post-market support.
The market is characterized by a high impact of regional expansion. Companies in the biotechnology and pharmaceutical sectors look for opportunities to access emerging markets with growing healthcare needs. Regional expansion allows them to establish a presence in these markets, collaborate with local partners, and tap into new patient populations. For instance, in January 2024, Parexel and the Japanese Foundation for Cancer Research (JFCR) formed a strategic alliance to enhance access to oncology clinical trials in Japan. Similarly, in September 2023, CTI Clinical Trial & Consulting Services opened state-of-the-art European Laboratory in Bilbao, Spain.
The consulting services segment dominated the market with the largest revenue share of over 24% in 2023. The segment is expected to maintain its position over the forecast period. This can be attributed to increasing M&A activities and constantly changing regulatory protocols. However, the pharma and biotech market has witnessed a continuous entry of new players, such as bioSyntagma, Signa Medical Writing, and Fieve Clinical Research, Inc. These players need to be compliant with set standards and norms, for which consulting is essential as these new entrants lack such capabilities.
The regulatory affairs segment is expected to witness the highest CAGR of 8.37% over the forecast period. Outsourcing trends for regulatory affairs has become an increasingly important practice in the healthcare industry. An increase in geographical expansion activities by companies that aim for speedy approvals in local markets is expected to contribute to the adoption of outsourcing models for regulatory services. Outsourcing market for regulatory affairs is expanding rapidly due to increased R&D activities, rising preference for personalized medicine and biologics augmenting overall volume of clinical trial applications and product registrations.
The pharmaceutical companies segment dominated the market with the largest revenue share in 2023. An increase in R&D spending by pharmaceutical companies for development of potential novel products and a rise in investments by CROs for development of core capabilities are expected to drive market demand in the region in the forthcoming years. Contract service providers are recognized as an effective strategic decision to curb the issues of drug shortfall and high production costs, as well as to meet the growing industry demand.
The biotechnology companies segment is expected to witness the fastest CAGR over the forecast period. This growth can be attributed to rapidly expanding biotech product pipelines, along with a trend toward biotechnology entities retaining their assets longer. Moreover, CROs concentrate on adapting their services to smaller biotechnology firms, which have emerged as prominent players in the clinical development of novel medicines and are responsible for driving innovation and expansion.
The biotechnology and pharmaceutical services outsourcing market of North America held a significant market share in 2023. This growth is attributed to the strong presence of several established CROs and CMOs, such as Thermo Fisher Scientific, Catalent, IQVIA, and Samsung Biologics, and growing R&D investments by life sciences and pharmaceutical companies in the region. The strong presence of stringent regulatory policies and a rise in R&D expenditure are among key factors that are likely to boost demand for outsourcing of services by pharmaceutical and biotechnology companies in the region. In addition, the expansion of several CMOs and CROs into the country is projected to propel market growth. For instance, in May 2022, Lonza expanded its inhalation facility at its Tampa (the U.S.) site to improve its capabilities in the development and manufacture of inhaled formulations
The biotechnology and pharmaceutical services outsourcing market in the U.S. held dominant share in North America in 2023. Pharmaceutical and biotechnology companies outsource part of their regulatory functions, such as report writing & publishing, clinical trial application services, and product design & maintenance, to regulatory service providers, thereby contributing to market growth. Moreover, outsourcing helps a company focus more on its core capabilities and improve its service delivery, thereby providing competitive advantage.
The biotechnology and pharmaceutical services outsourcing market in Asia Pacific region dominated the global market in 2023 and accounted for the largest share of over 40.00% of the overall revenue. The regional growth is owing to a rise in investments by developed countries and various regulatory reforms in clinical trial evaluation to align with the standards of various countries investing in the region. Low cost of drug development & manufacturing and availability of a skilled workforce is likely to foster contract development and manufacturing in this region. Moreover, economic policy reforms in countries, such as China, are anticipated to create an open and balanced economy, which presents ample growth opportunities for market players to invest in this region. For instance, in August 2022, Porton Advanced Solutions, a Chinese CDMO entity, raised USD 80 million to advance the cell and gene therapy platform.
The China biotechnology and pharmaceutical services outsourcing market held the largest share in 2023 in Asia Pacific. The country’s market growth is owing to entry of new players and service providers in the country, which can be attributed to stringent standards around patient safety in conducting clinical trials, easy access to a large patient pool, and cheap labor. In addition, low operating cost, increasing investments to improve technology, high R&D capacity, and rising adoption of global R&D standards to meet international requirements are some of the key factors responsible for the growing demand for regulatory & consulting services in China.
The biotechnology and pharmaceutical services outsourcing market in Japan is expected to grow substantially over the forecast period. Rising R&D costs prompt companies to outsource various stages of drug development to reduce expenses and focus on core competencies. Demand for specialized expertise in navigating complex regulatory requirements and advancing technologies drives outsourcing to contract research and manufacturing organizations in the country.
The India biotechnology and pharmaceutical services outsourcing market is anticipated to grow at the fastest CAGR over the forecast period. Cost benefits, improvements in infrastructure, and availability of expertise are some of the major factors driving growth of biotechnology/pharmaceutical services outsourcing market in the country. Western companies outsource their business processes to Asian countries such as India to gain competitive edge.
The biotechnology and pharmaceutical services outsourcing market in Europe is growing due to the demand for advanced medicines, which can be attributed to rising incidence of chronic & communicable diseases and rapidly aging population. Increase in consumption of advanced medicines is boosting the need for support from CROs.
The Germany biotechnology and pharmaceutical services outsourcing market is one of the largest pharmaceutical markets in the world after the U.S., China, Japan, and India and this is one of the major factors responsible for high demand for pharmaceutical and biotechnology contract services in the country. Moreover, Germany is known for its engineering and designing capabilities worldwide, hence services such as product design, consulting, product maintenance, and others are expected to contribute majorly in terms of revenue over the forecast period.
The biotechnology and pharmaceutical services outsourcing market in the UK is growing as the companies are outsourcing business activities to increase cost-efficiency, productivity, and focus on innovation. The companies are using hybrid-sourcing models across the value chain to strengthen their capabilities in areas of data management, logistics management, R&D, and analytics.
Latin America is one of the fastest-growing markets for outsourcing in pharmaceutical and biotechnology industries. The growth of this market can be attributed to various factors such as increase in the number of clinical trials and rise in the number of new players venturing into the medical devices market. Countries such as Brazil, Mexico, Venezuela, and Argentina are contributing to the growth of biotechnology/pharmaceutical services outsourcing market in Latin America.
The Brazil biotechnology and pharmaceutical services outsourcing market is one of the largest pharmaceutical markets in the world owing to the growing demand for pharmaceutical products. Moreover, the number of international pharmaceutical companies in the country has increased owing to easier access to private healthcare, enhanced national healthcare services coupled with improved business regulations, and generic drug market expansion through government policies. Hence, Brazil is expected to contribute considerably to the Latin America market during the forecast period.
The increase in the number of R&D projects and pharmaceutical companies in the region is expected to boost market growth during the forecast period. The country is adopting global standards and collaborating with other global CROs to mark its market presence. Moreover, MEA CRO industry offers advantages such as world-class medical facilities, well-developed infrastructure, and low operational cost, thereby boosting market growth.
The Saudi Arabia biotechnology and pharmaceutical services outsourcing market is growing as the establishment of universities focused on biotechnology and increase in the number of clinical research organizations with proven track records of conducting clinical trials are some of the factors driving the industry. Moreover, increase in the number of western-trained experts and rapid rise in healthcare investments are some of the factors expected to propel market growth during the forecast period.
The key companies are implementing several market strategies, such as merger & acquisition, collaboration, regional expansion, service portfolio expansion, and competitive pricing, to sustain in the competitive environment and acquire a higher market share. For instance, in May 2023, Vetter announced plans for the expansion of its production capacities and services at its Austrian site. This strategic move comes in response to rising demand from pharmaceutical clients, aiming to meet their evolving needs and address increased requirements for services, such as drug development, aseptic filling, and packaging.
The following are the leading companies in the biotechnology and pharmaceutical services outsourcing market. These companies collectively hold the largest market share and dictate industry trends.
In September 2023, ICON plc partnered with U.S. Biomedical Advanced Research and Development Authority (BARDA) for initiation of a clinical trial designed for evaluation of effectiveness of next-gen COVID-19 vaccine candidates.
In September 2023, Charles River Laboratories International, Inc. declared a collaboration agreement encompassing multiple programs to deploy Logica across various targets within the RS portfolio previously unexplored for drug development. Logica is an Artificial Intelligence (AI)-driven drug solution that converts biological insights into refined assets.
In September 2023, Syneos Health and Oracle extended their partnership. The companies hope to shorten the time it takes to find patients for clinical studies and broaden the patient populations taking part in medical research by utilizing the Oracle Cerner Learning Health Network (LHN) and some of Oracle's study startup solutions.
In May 2023, LabCorp declared its commitment to enhancing the enduring strategic collaboration with Providence through a newly established agreement. As part of this arrangement, LabCorp will acquire the outreach laboratory business of Providence Oregon and specific assets situated in Oregon.
In March 2023,Charles River launched Apollo, a cloud-based platform that assists drug developers in accessing study data, study milestones, documents, cost estimates, and program planning tools.
Report Attribute |
Details |
Market size value in 2024 |
USD 48.08 billion |
Revenue forecast in 2030 |
USD 66.95 billion |
Growth rate |
CAGR of 5.67% from 2024 to 2030 |
Actual data |
2018 - 2023 |
Forecast period |
2024 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2024 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Service, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; India; Japan; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; Saudi Arabia; UAE; South Africa, Kuwait |
Key companies profiled |
The Quantic Group; IQVIA; Parexel International Corporation; Lachman Consultant Services, Inc.; GMP Pharmaceuticals Pty Ltd.; Concept Heidelberg GmbH; LabCorp; Charles River Laboratories; ICON plc; Syneos Health; Lonza; Catalent Inc.; Samsung Biologics |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global biotechnology and pharmaceutical services outsourcing market report based on service, end-use, and region:
Service Outlook (Revenue, USD Million, 2018 - 2030)
Consulting
Regulatory Consulting
Clinical Development Consulting
Strategic Planning & Business Development Consulting
Quality Management Systems consulting
Others
Regulatory Affairs
Legal Representation
Regulatory Writing & Publishing
Product Registration & Clinical Trial Applications
Regulatory Submissions
Regulatory Operations
Others
Product Design & Development
Research, Strategy, & Concept Generation
Concept & Requirements Development
Detailed Design & Process Development
Design Verification & Validation
Process Validation & Manufacturing Transfer
Production & Commercial Support
Auditing and Assessment
Product Maintenance
Training & Education
Others
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical Companies
Biotech Companies
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global biotechnology and pharmaceutical services outsourcing market size was estimated at USD 46.15 billion in 2023 and is expected to reach USD 48.08 billion in 2024.
b. The global biotechnology and pharmaceutical services outsourcing market is expected to grow at a compound annual growth rate of 5.67% from 2024 to 2030 to reach USD 66.95 billion by 2030.
b. Key factors that are driving the biotechnology and pharmaceutical services outsourcing market growth include growing drug development costs coupled with high clinical development failure rates and increasing competition within the healthcare drug manufacturers.
b. Asia Pacific dominated the biotechnology and pharmaceutical services outsourcing market with a share of 40.0% in 2023. This is attributable to low cost of drug development & manufacturing and the availability of a skilled workforce is likely to foster contract development and manufacturing in this region.
b. Some key players operating in the biotechnology and pharmaceutical services outsourcing market include The Quantic Group; IQVIA; Parexel International Corporation; Lachman Consultant Services, Inc.; GMP Pharmaceuticals Pty Ltd.; Concept Heidelberg GmbH; LabCorp; Charles River Laboratories; ICON plc; Syneos Health; Lonza; Catalent Inc.; Samsung Biologics.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Details of primary research
1.6. Market Formulation & Validation
1.7. Region-wise Market Calculation
1.7.1. Region-Wise Market: Base Estimates
1.7.2. Global Market: CAGR Calculation
1.7.3. Region Based Segment Share Calculation
1.8. Model Details
1.8.1. Commodity flow analysis (Model 1)
1.8.1.1. Approach 1: Commodity flow approach
1.8.2. Value Chain-Based Sizing & Forecasting (Model 2)
1.8.3. QFD Model Sizing & Forecasting (Model 3)
1.8.4. Bottom-up Approach (Model 4)
1.9. Research Scope and Assumptions
1.10. List of Secondary Sources
1.11. List of Primary Sources
1.12. List of Abbreviations
1.13. Objectives
1.13.1. Objective 1
1.13.2. Objective 2
1.13.3. Objective 3
1.13.4. Objective 4
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Biotechnology and Pharmaceutical Services Outsourcing Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Outsourcing of R&D Activities
3.2.1.2. Changing Regulatory Landscape
3.2.1.3. Increasing Focus on Core Competencies by Pharmaceutical and Biotechnology Companies
3.2.1.4. Growing Drug Development Costs Coupled With High Clinical Development Failure Rates
3.2.1.5. Increasing Mergers and Collaborations
3.2.2. Market Restraint Analysis
3.2.2.1. Monitoring Issues and Lack of Standardization\
3.2.2.2. Loss of Control
3.2.2.3. Data Security Issues
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Clinical Trials Volume Analysis
3.6. R&D Investment Analysis
3.7. Biotechnology and Pharmaceutical Services Outsourcing Market Analysis Tools
3.7.1. Porter’s Five Forces Analysis
3.7.2. PESTEL Analysis
3.8. COVID-19 Impact Analysis
Chapter 4. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Movement Analysis
4.3. Global Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
4.4. Consulting
4.4.1. Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.2. Regulatory Consulting
4.4.2.1. Regulatory Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.3. Clinical Development Consulting
4.4.3.1. Clinical Development Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.4. Strategic Planning & Business Development Consulting
4.4.4.1. Strategic Planning & Business Development Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.5. Quality Management Systems Consulting
4.4.5.1. Quality Management Systems Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4.6. Others
4.4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Regulatory Affairs
4.5.1. Regulatory Affairs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.2. Legal Representation
4.5.2.1. Legal Representation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.3. Regulatory Writing & Publishing
4.5.3.1. Regulatory Writing & Publishing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.4. Product Registration & Clinical Trial Applications
4.5.4.1. Product Registration & Clinical Trial Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.5. Regulatory Submissions
4.5.5.1. Regulatory Submissions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.6. Regulatory Operations
4.5.6.1. Regulatory Operations Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5.7. Others
4.5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Product Design & Development
4.6.1. Product Design & Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Auditing and Assessment
4.7.1. Auditing and Assessment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Product Maintenance
4.8.1. Product Maintenance Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.9. Training & Education
4.9.1. Training & Education Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.10. Others
4.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Movement Analysis
5.3. Global Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
5.4. Pharmaceutical Companies
5.4.1. Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Biotech Companies
5.5.1. Biotech Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Estimates & Trend Analysis, by Service, by End-Use
6.1. Regional Dashboard
6.2. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Movement Analysis
6.3. North America
6.3.1. North America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2. U.S.
6.3.2.1. Key Country Dynamics
6.3.2.2. Competitive Scenario
6.3.2.3. Regulatory Framework
6.3.2.4. U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.3. Canada
6.3.3.1. Key Country Dynamics
6.3.3.2. Competitive Scenario
6.3.3.3. Regulatory Framework
6.3.3.4. Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Europe
6.4.1. Europe Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2. UK
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. UK Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Germany
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. Germany Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4. France
6.4.4.1. Key Country Dynamics
6.4.4.2. Competitive Scenario
6.4.4.3. Regulatory Framework
6.4.4.4. France Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.5. Italy
6.4.5.1. Key Country Dynamics
6.4.5.2. Competitive Scenario
6.4.5.3. Regulatory Framework
6.4.5.4. Italy Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.6. Spain
6.4.6.1. Key Country Dynamics
6.4.6.2. Competitive Scenario
6.4.6.3. Regulatory Framework
6.4.6.4. Spain Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.7. Denmark
6.4.7.1. Key Country Dynamics
6.4.7.2. Competitive Scenario
6.4.7.3. Regulatory Framework
6.4.7.4. Denmark Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.8. Sweden
6.4.8.1. Key Country Dynamics
6.4.8.2. Competitive Scenario
6.4.8.3. Regulatory Framework
6.4.8.4. Sweden Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.9. Norway
6.4.9.1. Key Country Dynamics
6.4.9.2. Competitive Scenario
6.4.9.3. Regulatory Framework
6.4.9.4. Norway Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Asia Pacific
6.5.1. Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. Japan
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. Japan Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. China
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. China Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. India
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. India Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.5. Australia
6.5.5.1. Key Country Dynamics
6.5.5.2. Competitive Scenario
6.5.5.3. Regulatory Framework
6.5.5.4. Australia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.6. Thailand
6.5.6.1. Key Country Dynamics
6.5.6.2. Competitive Scenario
6.5.6.3. Regulatory Framework
6.5.6.4. Thailand Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.7. South Korea
6.5.7.1. Key Country Dynamics
6.5.7.2. Competitive Scenario
6.5.7.3. Regulatory Framework
6.5.7.4. South Korea Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Latin America
6.6.1. Latin America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. Brazil
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. Brazil Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. Mexico
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. Argentina
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. Argentina Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Middle East & Africa
6.7.1. Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.2. South Africa
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework
6.7.2.4. South Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.3. Saudi Arabia
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework
6.7.3.4. Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.4. UAE
6.7.4.1. Key Country Dynamics
6.7.4.2. Competitive Scenario
6.7.4.3. Regulatory Framework
6.7.4.4. UAE Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.5. Kuwait
6.7.5.1. Key Country Dynamics
6.7.5.2. Competitive Scenario
6.7.5.3. Regulatory Framework
6.7.5.4. Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.1.1. Market Leaders
7.1.2. Emerging Players
7.2. Company Market Share/Assessment Analysis, 2023
7.3. Service Heat Map Analysis
7.4. Company Profiles
7.4.1. Parexel International Corporation
7.4.1.1. Company Overview
7.4.1.2. Financial Performance
7.4.1.3. Service Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. The Quantic Group
7.4.2.1. Company Overview
7.4.2.2. Financial Performance
7.4.2.3. Service Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. IQVIA
7.4.3.1. Company Overview
7.4.3.2. Financial Performance
7.4.3.3. Service Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Lachman Consultant Services, Inc.
7.4.4.1. Company Overview
7.4.4.2. Financial Performance
7.4.4.3. Service Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. GMP Pharmaceuticals Pty Ltd.
7.4.5.1. Company Overview
7.4.5.2. Financial Performance
7.4.5.3. Service Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Concept Heidelberg GmbH
7.4.6.1. Company Overview
7.4.6.2. Financial Performance
7.4.6.3. Service Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. LabCorp
7.4.7.1. Company Overview
7.4.7.2. Financial Performance
7.4.7.3. Service Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Charles River Laboratories
7.4.8.1. Company Overview
7.4.8.2. Financial Performance
7.4.8.3. Service Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. ICON plc.
7.4.9.1. Company Overview
7.4.9.2. Financial Performance
7.4.9.3. Service Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. Syneos Health
7.4.10.1. Company Overview
7.4.10.2. Financial Performance
7.4.10.3. Service Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. Lonza
7.4.11.1. Company Overview
7.4.11.2. Financial Performance
7.4.11.3. Service Benchmarking
7.4.11.4. Strategic Initiatives
7.4.12. Catalent Inc.
7.4.12.1. Company Overview
7.4.12.2. Financial Performance
7.4.12.3. Service Benchmarking
7.4.12.4. Strategic Initiatives
7.4.13. Samsung Biologics
7.4.13.1. Company Overview
7.4.13.2. Financial Performance
7.4.13.3. Service Benchmarking
7.4.13.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 4 Global Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 5 Global Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 6 Global Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 7 Global Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 8 Global Biotechnology and Pharmaceutical Services Outsourcing by Region, 2018 - 2030 (USD Million)
Table 9 North America Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
Table 10 North America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 11 North America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 12 North America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 13 North America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 14 North America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 15 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 16 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 17 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 18 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 19 U.S. Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 20 Canada Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 21 Canada Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 22 Canada Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 23 Canada Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 24 Canada Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 25 Europe Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
Table 26 Europe Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 27 Europe Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 28 Europe Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 29 Europe Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 30 Europe Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 31 Germany Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 32 Germany Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 33 Germany Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 34 Germany Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 35 Germany Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 36 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 37 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 38 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 39 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 40 U.K. Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 41 France Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 42 France Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 43 France Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 44 France Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 45 France Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 46 Italy Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 47 Italy Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 48 Italy Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 49 Italy Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 50 Italy Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 51 Spain Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 52 Spain Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 53 Spain Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 54 Spain Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 55 Spain Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 56 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 57 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 58 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 59 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 60 Denmark Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 61 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 62 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 63 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 64 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 65 Sweden Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 66 Norway Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 67 Norway Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 68 Norway Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 69 Norway Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 70 Norway Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 71 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
Table 72 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 73 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 74 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 75 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 76 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 77 China Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 78 China Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 79 China Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 80 China Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 81 China Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 82 Japan Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 83 Japan Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 84 Japan Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 85 Japan Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 86 Japan Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 87 India Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 88 India Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 89 India Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 90 India Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 91 India Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 92 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 93 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 94 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 95 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 96 South Korea Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 97 Australia Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 98 Australia Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 99 Australia Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 100 Australia Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 101 Australia Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 102 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 103 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 104 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 105 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 106 Thailand Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 107 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
Table 108 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 109 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 110 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 111 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 112 Latin America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 113 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 114 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 115 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 116 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 117 Brazil Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 118 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 119 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 120 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 121 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 122 Mexico Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 123 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 124 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 125 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 126 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 127 Argentina Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 128 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
Table 129 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 130 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 131 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 132 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 133 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 134 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 135 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 136 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 137 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 138 South Africa Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 139 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 140 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 141 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 142 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 143 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 144 UAE Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 145 UAE Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 146 UAE Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 147 UAE Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 148 UAE Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
Table 149 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
Table 150 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
Table 151 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
Table 152 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
Table 153 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 Biotechnology and Pharmaceutical Services Outsourcing, Market Segmentation
Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 10 Porter’s Five Forces Analysis
Fig. 11 Regional Marketplace: Key Takeaways
Fig. 12 Global Biotechnology and Pharmaceutical Services Outsourcing, for Consulting, 2018 - 2030 (USD Million)
Fig. 13 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Consulting, 2018 - 2030 (USD Million)
Fig. 14 Global Biotechnology and Pharmaceutical Services Outsourcing, for Clinical Development Consulting, 2018 - 2030 (USD Million)
Fig. 15 Global Biotechnology and Pharmaceutical Services Outsourcing, for Strategic Planning & Business Development Consulting, 2018 - 2030 (USD Million)
Fig. 16 Global Biotechnology and Pharmaceutical Services Outsourcing, for Quality Management Systems Consulting, 2018 - 2030 (USD Million)
Fig. 17 Global Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
Fig. 18 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Affairs, 2018 - 2030 (USD Million)
Fig. 19 Global Biotechnology and Pharmaceutical Services Outsourcing, for Legal Representation, 2018 - 2030 (USD Million)
Fig. 20 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
Fig. 21 Global Biotechnology and Pharmaceutical Services Outsourcing, for Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
Fig. 22 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Submissions, 2018 - 2030 (USD Million)
Fig. 23 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Operations, 2018 - 2030 (USD Million)
Fig. 24 Global Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
Fig. 25 Global Biotechnology and Pharmaceutical Services Outsourcing, for Product Design & Development, 2018 - 2030 (USD Million)
Fig. 26 Global Biotechnology and Pharmaceutical Services Outsourcing, for Research, Strategy, & Concept Generation, 2018 - 2030 (USD Million)
Fig. 27 Global Biotechnology and Pharmaceutical Services Outsourcing, for Concept & Requirements Development, 2018 - 2030 (USD Million)
Fig. 28 Global Biotechnology and Pharmaceutical Services Outsourcing, for Detailed Design & Process Development, 2018 - 2030 (USD Million)
Fig. 29 Global Biotechnology and Pharmaceutical Services Outsourcing, for Design Verification & Validation , 2018 - 2030 (USD Million)
Fig. 30 Global Biotechnology and Pharmaceutical Services Outsourcing, for Process Validation & Manufacturing Transfer , 2018 - 2030 (USD Million)
Fig. 31 Global Biotechnology and Pharmaceutical Services Outsourcing, for Production & Commercial Support, 2018 - 2030 (USD Million)
Fig. 32 Global Biotechnology and Pharmaceutical Services Outsourcing, for Pharmaceutical Companies, 2018 - 2030 (USD Million)
Fig. 33 Global Biotechnology and Pharmaceutical Services Outsourcing, for Biotech Companies, 2018 - 2030 (USD Million)
Fig. 34 Regional Outlook, 2023 & 2030
Fig. 35 North America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 36 U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 37 Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 38 Europe Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 39 Germany Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 40 UK Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 41 France Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 42 Italy Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 43 Spain Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 44 Denmark Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 45 Sweden Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 46 Norway Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 47 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 48 Japan Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 49 China Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 50 India Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 51 Australia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 52 South Korea Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 53 Thailand Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 54 Latin America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 55 Brazil Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 56 Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 57 Argentina Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 58 Middle East and Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 59 South Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 60 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 61 UAE Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 62 Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Market Segmentation
Industry is witnessing outsourcing; many patents of many drugs are expected to expire soon, which is anticipated to drive the biosimilar market. This, in turn, is expected to boost R&D activities of companies for commercializing generic versions of drugs. Launching generics in the market in a feasible timeline and cost is anticipated to drive the demand for global Contract Research Organizations (CROs). In 2015, the top 30 sponsor companies had allied with at least one CRO. It has been observed that significant players have three alliances on average to maintain their product portfolios. A pharmaceutical company engages multiple CROs, each providing a unique service. Companies invest in R&D to gain a competitive advantage; pharmaceutical and biotechnology companies allocate a significant portion of their revenue to R&D activities.
The regulatory approval process is becoming more stringent and time-consuming, and to gain a more significant market share, market players are striving to receive product approvals at the first attempt. Pharmaceutical and biotechnology companies must have an in-house regulatory department or outsource their regulatory affairs functions due to stringent regulatory requirements in developed countries and changing regulations in developing countries. Companies are outsourcing biotech/pharmaceutical services based on project size and priority due to the difficulty of establishing in-house regulatory affairs departments in offshore countries.
Pharmaceutical companies must manage continuous changes in regulatory requirements, spanning different business activities and multiple geographies. Noncompliance with changing regulatory requirements may result in penalties and delays, which may lead to loss of revenue. Medical device companies' geographic expansion aimed at speedy approvals in global markets is expected to further contribute to an increase in the adoption of outsourcing models for regulatory affairs and consulting services.
Managing and controlling outsourced services performed by Contract Research Organizations (CROs) is complex. There is a lack of standardization as not all CROs comply with international regulatory requirements, which may adversely affect the quality of services. Therefore, pharmaceutical and biotechnology companies are now outsourcing only lower-end functions and prefer performing high-end functions in-house. Standardization and authenticity of documented data are significant issues, as many small-scale companies need digital documentation capabilities. However, service providers are trying to comply with international standards of regulatory authorities such as the U.S. FDA to overcome this difficult challenge.
This section will provide insights into the contents included in this biotechnology and pharmaceutical services outsourcing market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.
Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
Company overview
Financial performance
Product benchmarking
Latest strategic developments
Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance
A three-pronged approach was followed for deducing the biotechnology and pharmaceutical services outsourcing market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:
Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for biotechnology and pharmaceutical services outsourcing market to gather the most reliable and current information possible.
Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of biotechnology and pharmaceutical services outsourcing market data depending on the type of information we’re trying to uncover in our research.
Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.
Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.
Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.
Qualitative Functional Deployment (QFD) Modelling for market share assessment.
Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.
Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.
Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.
This step also entails the finalization of the report scope and data representation pattern.
Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.
The biotechnology and pharmaceutical services outsourcing market was categorized into three segments, namely service (Consulting, Auditing & Assessment, Regulatory Affairs, Product Maintenance, Product Design & Development, Product Testing & Validation, Training & Education), end-use (Pharma, Biotech), regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).
The biotechnology and pharmaceutical services outsourcing market was segmented into service, end-use, and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:
Demand estimation of each product across countries/regions summed up to from the total market.
Variable analysis for demand forecast.
Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.
Primary interviews for data revalidation and insight collection.
Used extensively for new product forecasting or analyzing penetration levels.
Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.
Primary interviews and vendor-based primary research for variable impact analysis.
The biotechnology and pharmaceutical services outsourcing market was analyzed at a regional level. The globe was divided into North America, Europe, Asia Pacific, Latin America, Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-three countries, namely, the U.S.; Canada; the UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; Thailand; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait.
All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.
The biotechnology and pharmaceutical services outsourcing market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:
THE QUANTIC GROUP - The Quantic Group provides industry and government biotechnology and pharmaceutical consulting services. It operates through various segments, such as regulatory affairs, research, development, manufacturing, and quality operations. Quantic has supportive clients from all over the globe that mainly operate in regulatory affairs. It also provides services in other segments such as marketing & manufacturing strategies, clinical trial practices, research & development, product, manufacturing & quality systems methodologies, and others.
IQVIA HOLDINGS, INC. - IQVIA Holdings, Inc. is one of the leading companies that provides contract research services, technology solutions, and advanced analytics to the global life sciences industry. The company operates through three main business areas- R&D solutions, commercialization solutions, and technology solutions. It serves biotechnology, consumer health, pharmaceuticals, and device & diagnostics companies in North America, Europe, Asia Pacific, and Africa. IQVIA also serves pharmacies, pharmaceutical distributors, payers, and government & regulatory agencies.
PAREXEL INTERNATIONAL CORPORATION - Parexel International Corporation is a healthcare company that provides biopharmaceutical and pharmaceutical services worldwide. It provides biopharmaceutical services to various clients across the globe and also offers new treatment options for various rare disorders. It serves biotechnology, consumer health companies, pharmaceutical, and device & diagnostic companies in North America, Europe, Asia Pacific, and Africa. It operates through different segments, such as clinical trials, regulatory, consulting, and market access. It provides services to more than 100 countries. They also outsource their services to different pharmacies, pharmaceutical distributors, payers, & regulatory agencies.
LACHMAN CONSULTANT SERVICES - Lachman Consultant Services provides technical and regulatory affairs services to clients worldwide. It also consults other organizations to solve their problems and develop effective strategies for approval of new drugs and devices. It also provides consulting services to global clients such as pharmaceutical, biotechnology, medical devices, and dietary supplement companies. It provides services in North America, Europe, and Asia Pacific regions.
GMP PHARMACEUTICALS - GMP Pharmaceuticals is one of the leading manufacturers of medicines, natural health products, and infant formulas. It serves health food companies across the globe. For example, it has around 20 years of experience providing worldwide nutritional and health food services. GMP Pharmaceuticals manufactures various pharmaceutical products such as coated & uncoated tablets, liquids, capsules, creams, ointments, and powders. It is the only contract manufacturer in Australia and New Zealand.
CONCEPT HEIDELBERG GMBH - Concept Heidelberg GmbH is one of the leading organizations in Europe that provides training and information services in pharmaceutical quality assurance and drug quality. It organizes more than 350 seminars and conferences at least in 10 European countries every year. It provides GMP/GDP services to various pharmaceutical & biopharmaceutical industries, such as in-house training, e-learning, and consulting services.
COVANCE, INC. - Covance, Inc. is a contract research organization that provides clinical and commercialization services to the biopharmaceutical and pharmaceutical industries. LabCorp owns the company. It provides its services over 60 countries. Covance is the world's most wide-ranging drug development company that delivers solutions to pharmaceutical industries. It also offers laboratory testing services to chemical industries and is a market leader in discovery, toxicology, & central laboratory services. It is one of the top companies that provides management services in phase III clinical trials to pharmaceutical industries.
CHARLES RIVER - Charles River Laboratory provides clinical laboratory and preclinical services for the pharmaceutical and biotechnology industries. Charles operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support. Its DSA segment offerings include bioanalysis, drug metabolism, toxicology, and pharmacokinetics services. It caters its products and services to biotechnology and pharmaceutical companies, medical device companies, hospitals, clinics, and academic institutions. The company provides its products in about 20 countries and has a presence in Canada, Finland, Belgium, France, Hungary, Germany, Italy, China, Italy, Japan, Spain, the Netherlands, and the UK.
PRA HEALTH SCIENCES - PRA Health Sciences provides outsourced clinical development and data solution services to biopharmaceutical & pharmaceutical industries globally. It operates in different therapeutic areas, such as immunology, inflammation, and infectious diseases. The company provides services to various geographic regions such as North America, Europe, Asia, Latin America, South Africa, Australia, and the Middle East.
ICON PLC - ICON provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries globally. The company specializes in the strategic development, management, and analysis of programs that support Clinical Development from compound selection to Phase I-IV clinical studies. The company offers a complete range of services, including consulting, development, and commercialization, from a global network of offices in 37 countries.
Supply Side Estimates
Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.
Segment revenue determination via variable analysis and penetration modeling.
Competitive benchmarking to identify market leaders and their collective revenue shares.
Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.
Demand side estimates
Identifying parent markets and ancillary markets
Segment penetration analysis to obtain pertinent
revenue/volume
Heuristic forecasting with the help of subject matter experts
Forecasting via variable analysis
Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.
Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.
Understanding market estimates and forecasts (with the base year as 2022, historic information from 2018 to 2021, and forecast from 2023 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.
The report provides market value for the base year 2022 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.
The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.
We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.
All market estimates and forecasts have been validated through primary interviews with the key industry participants.
Inflation has not been accounted for to estimate and forecast the market.
Numbers may not add up due to rounding off.
Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).
Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).
Latin America includes Central American countries and the South American continent
Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.
GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.
We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:
Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.
Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.
The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."